{"id":"capecitabine-and-bevacizumab","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Hand-foot skin reaction"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Nausea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Bleeding"},{"rate":"5-10","effect":"Thromboembolism"},{"rate":"10-15","effect":"Proteinuria"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that is metabolized to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and incorporates into RNA and DNA to impair cancer cell proliferation. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. The combination leverages chemotherapy-induced cytotoxicity with anti-angiogenic effects.","oneSentence":"Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:07:44.557Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07490262","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2026-03-31","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":680},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT04158258","phase":"","title":"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-02-21","conditions":"Breast Cancer","enrollment":2907},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07462143","phase":"PHASE2, PHASE3","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-04-30","conditions":"Colorectal (Colon or Rectal) Cancer","enrollment":700},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07446387","phase":"PHASE2","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":70},{"nctId":"NCT02669173","phase":"PHASE1","title":"Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2016-10-11","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT05171660","phase":"PHASE3","title":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-08","conditions":"Colorectal Cancer Stage IV","enrollment":446},{"nctId":"NCT07407465","phase":"PHASE2","title":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-10-20","conditions":"Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT07392866","phase":"PHASE2, PHASE3","title":"A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":120},{"nctId":"NCT07395063","phase":"PHASE2","title":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT04854668","phase":"PHASE3","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-05-27","conditions":"Metastatic Colorectal Cancer","enrollment":748},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT07362264","phase":"PHASE1","title":"A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2025-07-01","conditions":"Liver Cancer","enrollment":50},{"nctId":"NCT07005570","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","status":"RECRUITING","sponsor":"Dechang Diao","startDate":"2025-05-01","conditions":"pMMR/MSS Locally Advanced Rectal Cancer","enrollment":86},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT07347951","phase":"PHASE2","title":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT04564898","phase":"PHASE1, PHASE2","title":"Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Colorectal Cancer Metastatic","enrollment":48},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT02314182","phase":"PHASE3","title":"GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-11-20","conditions":"Rectal Adenocarcinoma","enrollment":5},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT07283367","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-12-19","conditions":"CRC","enrollment":502},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT06703177","phase":"PHASE1, PHASE2","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-18","conditions":"Advanced Solid Tumors","enrollment":876},{"nctId":"NCT01081262","phase":"PHASE3","title":"Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-12","conditions":"Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma","enrollment":50},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT01191697","phase":"PHASE2","title":"CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-02","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":37},{"nctId":"NCT05609370","phase":"PHASE1, PHASE2","title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-29","conditions":"Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","enrollment":113},{"nctId":"NCT07198165","phase":"PHASE2","title":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-05","conditions":"Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer, Radiotherapy","enrollment":104},{"nctId":"NCT01061515","phase":"PHASE1","title":"Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2011-05-10","conditions":"Carcinoma","enrollment":21},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT07117435","phase":"PHASE1","title":"Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-05-13","conditions":"Colorectal Liver Metastases, First-line Treatment","enrollment":7},{"nctId":"NCT07114627","phase":"","title":"Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-02-18","conditions":"Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer","enrollment":66},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT07059949","phase":"PHASE2","title":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-30","conditions":"Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy","enrollment":80},{"nctId":"NCT07051785","phase":"PHASE2","title":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liu Huang","startDate":"2025-07-07","conditions":"Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT07025239","phase":"PHASE3","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-07","conditions":"Metastatic Colorectal Cancer","enrollment":430},{"nctId":"NCT07007728","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver","enrollment":54},{"nctId":"NCT02420509","phase":"","title":"Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2015-08-27","conditions":"Cancer","enrollment":2},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT06839105","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-02-21","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor","enrollment":214},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06973343","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-05","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT06949982","phase":"PHASE2","title":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes","status":"RECRUITING","sponsor":"Sergey Orlov, MD","startDate":"2025-03-17","conditions":"Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms","enrollment":60},{"nctId":"NCT04245865","phase":"PHASE2","title":"Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vejle Hospital","startDate":"2020-06-26","conditions":"Colorectal Cancer Metastatic","enrollment":83},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT05299476","phase":"PHASE2","title":"CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-04-25","conditions":"Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5","enrollment":32},{"nctId":"NCT06881537","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-06-01","conditions":"Locally Recurrent Colorectal Cancer","enrollment":15},{"nctId":"NCT05585814","phase":"PHASE2","title":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-05-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT03396926","phase":"PHASE2","title":"Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-18","conditions":"Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7","enrollment":44},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Metastatic Pancreatic Cancer","enrollment":""},{"nctId":"NCT03167177","phase":"PHASE1, PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03169738","phase":"PHASE1, PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03167164","phase":"PHASE1, PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT06835179","phase":"PHASE2","title":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer","enrollment":28},{"nctId":"NCT06282445","phase":"PHASE2","title":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-03-01","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06825624","phase":"PHASE1","title":"ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-10-03","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":560},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT06788171","phase":"PHASE2","title":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-03-01","conditions":"Colorectal Cancer Liver Metastasis","enrollment":35},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00780494","phase":"PHASE2","title":"Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-02","conditions":"Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction","enrollment":35},{"nctId":"NCT06753721","phase":"PHASE1, PHASE2","title":"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-12-31","conditions":"Advanced Colorectal Adenocarcinoma","enrollment":13},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT01531595","phase":"PHASE2","title":"Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pia Osterlund","startDate":"2012-02","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT03329248","phase":"PHASE1, PHASE2","title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-11-06","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04940546","phase":"PHASE1, PHASE2","title":"Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-06-16","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06550453","phase":"PHASE4","title":"Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"yangjianjun","startDate":"2024-09-01","conditions":"Locally Advanced Colorectal Cancer","enrollment":20},{"nctId":"NCT06667050","phase":"PHASE2","title":"CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2024-10-10","conditions":"Gastric Adenocarcinoma","enrollment":58},{"nctId":"NCT04456699","phase":"PHASE3","title":"Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-19","conditions":"Metastatic Colorectal Cancer","enrollment":335},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bevacizumab (Avastin )","Capecitabine (Xeloda)"],"phase":"phase_2","status":"active","brandName":"Capecitabine and Bevacizumab","genericName":"Capecitabine and Bevacizumab","companyName":"South Eastern European Research Oncology Group","companyId":"south-eastern-european-research-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}